We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeli... Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States. Show more
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire CUPERTINO, Calif., March 27, 2024 - Ongoing Communication with FDA to Align...
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update PR Newswire CUPERTINO, Calif., March 20, 2024 CUPERTINO, Calif., March 20, 2024...
0001082038false00010820382024-03-042024-03-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report...
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZETยฎ Product Line in U.S. and Canada PR Newswire CUPERTINO, Calif., March 4, 2024 Partnership...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND...
DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference PR Newswire CUPERTINO, Calif., Feb. 7, 2024 CUPERTINO, Calif., Feb. 7, 2024 /PRNewswire/ -- DURECT...
0001082038false00010820382023-12-212023-12-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.09 | 7.2 | 1.25 | 1.34 | 1.15 | 131808 | 1.27114873 | CS |
4 | 0.3562 | 36.2065460459 | 0.9838 | 1.41 | 0.94 | 183232 | 1.14949178 | CS |
12 | 0.8204 | 157.890685142 | 0.5196 | 1.41 | 0.51 | 208318 | 0.89622102 | CS |
26 | -1.23 | -47.859922179 | 2.57 | 3.14 | 0.4703 | 499254 | 1.01001031 | CS |
52 | -3.05 | -69.4760820046 | 4.39 | 7.46 | 0.4703 | 347988 | 1.81706064 | CS |
156 | -17.96 | -93.0569948187 | 19.3 | 20.5 | 0.4703 | 494146 | 7.53387534 | CS |
260 | -5.019 | -78.9275043246 | 6.359 | 41 | 0.4703 | 784621 | 15.51121162 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions